OncoMatch/Clinical Trials/NCT06836492

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Is NCT06836492 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies VAC，VAC/VII，CAV/IE for rhabdomyosarcoma.

Phase 3RecruitingYizhuo ZhangNCT06836492Data as of Jun 2026Location: China

Treatment: VAC，VAC/VII，CAV/IE — The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

VAC，VAC/VII，CAV/IE

Cancer type

Rhabdomyosarcoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages 0–18

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06836492 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 18 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Rhabdomyosarcoma trials